Australian biotech market watch 31/07/09
Friday, 31 July, 2009
On this last day of Dry July and the All Ordinaries is in anything but a sober state; this week has seen consistent rises to new highs since the market hit bottom in March. As of mid-afternoon, the All Ords is 4,348, up 1.24% for the day after gains in the US markets overnight.
The Health Care indices have had some little trouble keeping up with the banks and miners though, dropping a third of a percent from today's open.
Manufacturer of miniature implantable heart pumps, HeartWare International (ASX:HIN), reeled yesterday from news the United States Federal Trade Commission had filed a complaint about its proposed acquisition by medical device company, Thoratec. However, it rallied again today, bouncing back 22% to $0.795, recovering most of its losses from Thursday.
Universal Biosensors (ASX:UBI) had a good day, lifting 8.33% to $0.91, although this comes after a series of drops from $1.00 around mid-July.
Fisher & Paykel Healthcare (ASX:FPH) has continued its strong run, up 5.8% today to $2.71, it's highest price since February.
CSL (ASX:CSL) shed a wee 12c to $30.35 after a strong week saw it rise from Monday's opening price of $29.63. The rest of the Big Three remained fairly stable, with Cochlear (ASX:COH) not moving much and ResMed wobbling slightly, but buoyed by bullish outlooks by analysts.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
